![Joern-Peter Halle](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Joern-Peter Halle
Corporate Officer/Principal chez
MERCK KGAA
Profil
Dr. Joern-Peter Halle is a Venture Partner at Biogeneration Management BV and a Chief Strategy Officer at Merck KGaA.
Dr. Halle also served on the board at iOnctura SA.
He received his doctorate degree from Universität Konstanz.
Postes actifs de Joern-Peter Halle
| Sociétés | Poste | Début |
|---|---|---|
| MERCK KGAA | Corporate Officer/Principal | 01/01/2022 |
Biogeneration Management BV
 Biogeneration Management BV Investment ManagersFinance Biogeneration Management invests in companies located in the United States, Netherlands and Europe. The firm targets companies operating in the fields of biotechnology sectors. It provides financing for pre-seed, seed and early stage capital requirements. It also acts as lead investor. | Private Equity Investor | 01/04/2024 |
Anciens postes connus de Joern-Peter Halle
| Sociétés | Poste | Fin |
|---|---|---|
iOnctura SA
 iOnctura SA BiotechnologyHealth Technology Develops therapies that extend health span for cancer patients | Directeur/Membre du Conseil | - |
Formation de Joern-Peter Halle
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
32
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Merck KGaA
 Merck KGaA Pharmaceuticals: MajorHealth Technology Engages in the manufacturing of pharmaceutical and chemical products | Health Technology |
Universität Konstanz
 Universität Konstanz Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Biogeneration Management BV
Biogeneration Management BV Investment ManagersFinance Biogeneration Management invests in companies located in the United States, Netherlands and Europe. The firm targets companies operating in the fields of biotechnology sectors. It provides financing for pre-seed, seed and early stage capital requirements. It also acts as lead investor. | Finance |
iOnctura SA
iOnctura SA BiotechnologyHealth Technology Develops therapies that extend health span for cancer patients | Health Technology |
